Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fixed-dose versus weight-based ivermectin for uncomplicated strongyloidiasis
2024-515968-32-00Phase 2Authorised
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of ivermectin in strongyloidiasis (2 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Microbiological cure at 6 months. Planned start Jul 2024; status: authorised.
02
Drugs
ivermectin
03
Conditions
strongyloidiasis
Beyond the preview
Go deeper on 2024-515968-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515968-32-00.